Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · Real-Time Price · USD
0.6199
-0.0127 (-2.01%)
Oct 2, 2026, 4:00 PM EDT - Market closed

Biodexa Pharmaceuticals Financials Overview

Millions GBP. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---0.380.70.58
Revenue Growth
----45.49%20.93%68.51%
Gross Profit
-5.21-3.96-5.44-3.69-4.41-4.08
Operating Income
-8.84-8.65-9.2-8.01-8.93-7
Net Income
-4.42-6.38-5.73-7.08-7.66-5.46
Earnings Per Share
-9.66-58.18----
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
3.238.531.675.972.8410.06
Total Debt
-0.060.730.460.620.77
Net Cash (Debt)
3.238.470.945.512.219.29
Net Cash Growth
-61.88%799.47%-82.89%148.96%-76.19%27.52%
Net Cash Per Share
7.0677.22----

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-6.9-5.59-12.26-6.83-7.05-6.01
Capital Expenditures
-0.01-0-0.01-0.03-0.06-0.32
Free Cash Flow
-6.91-5.59-12.27-6.85-7.11-6.33
Free Cash Flow Growth
------

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
------
Operating Margin
----2103.41%-1277.83%-1210.73%
Pretax Margin
----1964.57%-1214.31%-1056.40%
Profit Margin
----1858.01%-1095.28%-944.64%
FCF Margin
----1798.42%-1017.17%-1094.81%

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
---14.464.6816.10